halcinonide
Sources réglementaires consultées
Indications approuvées
- Soulagement des manifestations inflammatoires et prurigineuses des dermatoses répondant aux corticoïdes.
Contre-indications
Absolues
- Hypersensibilité à la halcinonide ou à l’un des composants.
Mises en garde cliniques
- Mise en garde majeure · Utiliser la plus petite quantité efficace pendant la durée la plus courte possible. Les grandes surfaces, l’usage prolongé, l’altération de la barrière cutanée et l’occlusion augmentent l’absorption et peuvent provoquer une suppression réversible de l’axe HHS, un syndrome de Cushing, une hyperglycémie ou une glycosurie ; les enfants sont plus sensibles. — DailyMed/openFDA, SPL set ID 42dc0904-1800-5f3b-e063-6294a90a2ad2
- Éviter le contact avec les yeux. Arrêter en cas d’irritation ou de sensibilisation. Traiter toute infection cutanée ; en l’absence de réponse rapide, arrêter le corticoïde jusqu’à son contrôle. — DailyMed/openFDA, SPL set ID 42dc0904-1800-5f3b-e063-6294a90a2ad2
- Sous occlusion, surveiller également une altération de la thermorégulation. Ne pas utiliser par voie ophtalmique. — DailyMed/openFDA, SPL set ID 42dc0904-1800-5f3b-e063-6294a90a2ad2
Grossesse et allaitement
Pendant la grossesse, n’utiliser que si le bénéfice potentiel justifie le risque et éviter les quantités importantes ou les périodes prolongées. Utiliser avec prudence pendant l’allaitement.
Bibliographie récente (PubMed)
This prospective, open-label study evaluated the effectiveness and safety of tildrakizumab plus topical halcinonide ointment in psoriasis patients. Adults (age greater than or equal to 18 years) with moderate to severe plaque psoriasis (body surface area [BSA] greater than or equal to 10%, physician's global assessment [PGA] greater than or equal to 3, psoriasis area severity index [PASI] greater than or equal to 12) received tildrakizumab (100 mg; s.c.) at weeks 0, 4, and 16. Patients with BSA >3% at week 16 received additional halcinonide 0.1% twice daily for 4 weeks (week 20) and were followed for another 4 weeks (week 24); those with BSA less than or equal to 3% were followed to week 24. Twenty-five patients were enrolled (mean age 52.6 years; 68% male). The proportion of all patients achieving BSA less than or equal to 3% was 52.2% at week 16, 73.7% at week 20 (after 4 weeks of adjunctive halcinonide in patients with BSA >3% at week 16), and 84.2% at week 24 (4 weeks after halcinonide discontinuation). PASI 75 was attained in 60.9% of all patients at week 16, and 73.7% at weeks 20 and 24. In patients adding halcinonide, improvements from baseline in mean BSA, PGA, and PGA x BSA increased from week 16 (55%, 29%, and 64%, respectively) to week 20 (78%, 51%, and 88%, respectively), and were maintained through week 24. Quality of life improved with tildrakizumab monotherapy and further with adjunctive halcinonide. Adverse events (AEs) were infrequent. No serious AEs or discontinuations due to AEs were noted. Tildrakizumab plus topical halcinonide ointment is safe and effective in controlling psoriasis for patients inadequately responding to tildrakizumab monotherapy.Bagel J, Novak K, Nelson E. Tildrakizumab in combination with topical halcinonide 0.1% ointment for treating moderate to severe plaque psoriasis. J Drugs Dermatol. 2023;22(8):766-772. doi:10.36849/JDD.6830.